Clinical trial
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
NCT00187512 · University of California, San Francisco, Other · Recruiting
Key facts
| NCT number | NCT00187512 |
|---|---|
| Title | SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era |
| Official title | SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era |
| Acronym | SCOPE |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Recruiting |
| Study type | Observational |
| Conditions | HIV Infections |
| Enrollment | 2,500 |
| Start date | Mar 1, 2000 |
| Primary completion | Dec 1, 2032 |
| Completion | Dec 1, 2033 |
| First posted | Sep 16, 2005 |
| Last update posted | Jul 8, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: